| |
[摘要]：Sodium/glucose cotransporters (SGLTs) serve a critical role in the reclamation of glucose in the kidney. Blocking this reabsorption, and thus increasing the amount of glucose excretion, has been proposed as a novel strategy for treating diabetes. Canagliflozin is a C-glucoside with a thiophene ring that acts as a sodium/glucose cotransporter 2 (SGLT2) inhibitor. Although further data from multiple ongoing phase III clinical trials of canagliflozin and other SGLT2 inhibitors are forthcoming, results to date suggest that the benefits of SGLT2 inhibition may be achieved without causing significant adverse effects. This review will provide a description of the role of the kidney in glucose homeostasis and summarize the preclinical and clinical studies published thus far on canagliflozin. |
|
